On September 8, 2021 BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecules for traditionally undruggable targets, reported that Irene Yuan, Co-Founder and Executive Vice President of BridGene Biosciences, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021 (Press release, Bridgene Biosciences, SEP 8, 2021, https://www.prnewswire.com/news-releases/bridgene-biosciences-to-present-at-the-virtual-hc-wainwright-23rd-annual-global-investment-conference-301370895.html [SID1234587444]). The prerecorded presentation will be available starting at 7 a.m. ET on September 13, 2021, and can be accessed via the conference’s virtual platform by registered conference attendees.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the presentation, Ms. Yuan will provide an overview of BridGene’s proprietary chemoproteomics platform technology, IMTAC (Isobaric Mass Tagged Affinity Characterization), and highlight recent corporate achievements. Currently, about 90% of disease-causing proteins cannot be targeted by traditional therapies due to the lack of a known addressable binding site. BridGene intends to change this by using its IMTAC platform. IMTAC enables the screening of small molecules against all the proteins in live cells to discover drug candidates for high value and hard-to-drug targets that cause disease. BridGene can perform IMTAC screening for both covalent and non-covalent molecules, setting the company apart from its peers. By combining IMTAC with phenotypic screening, BridGene can also discover previously unknown mechanisms for disease treatments by identifying new targets responsible for disease characteristics in cell models, a unique differentiator from its peers.
Ms. Yuan, Dr. Ping Cao (Co-Founder and Chief Executive Officer of BridGene), and other members of the BridGene management team will be participating in virtual one-on-one meetings.